Generic LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE INN entry, pharmaceutical patent and freedom to operate

Sponsor	Phase
Johns Hopkins University	Phase 1/Phase 2
The Aurum Institute NPC	Phase 1/Phase 2
ANRS, Emerging Infectious Diseases	Phase 4

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Micro Labs	LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE	lamivudine; nevirapine; zidovudine	TABLET;ORAL	205626-001	Aug 13, 2018		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 9, 2026

Lamivudine, nevirapine and zidovudine are mature, off-patent antiretroviral medicines with sharply different commercial prospects. Lamivudine retains strategic value as a nucleoside reverse transcriptase inhibitor in HIV and hepatitis B treatment. Zidovudine and nevirapine have declined substantially because global treatment programs have shifted toward dolutegravir-based regimens, particularly tenofovir disoproxil fumarate, lamivudine and dolutegravir, known as TLD.

The three-drug combination has limited commercial value in developed markets. Its remaining demand is concentrated in low- and middle-income countries, pediatric formulations, prevention of mother-to-child transmission, emergency procurement and price-sensitive public-sector tenders. Patent barriers are negligible. The principal competitive issues are procurement pricing, regulatory registration, quality compliance, manufacturing scale and inclusion in national treatment guidelines.

What is the commercial status of lamivudine, nevirapine and zidovudine?

Lamivudine, nevirapine and zidovudine are generic small-molecule antiretrovirals. They are available as individual products and in fixed-dose combinations.

Drug	Class	Primary historical role	Current commercial position
Lamivudine	NRTI	HIV backbone; hepatitis B treatment	Commercially durable, especially in generic combinations
Zidovudine	NRTI	Early HIV treatment; prevention of mother-to-child transmission	Mature and declining
Nevirapine	NNRTI	Early triple therapy; prevention of mother-to-child transmission	Mature and declining, with limited programmatic use
Lamivudine/zidovudine/nevirapine	Two NRTIs plus one NNRTI	Low-cost triple therapy	Legacy regimen with residual public-sector demand

Lamivudine remains relevant because it is inexpensive, orally administered and compatible with multiple antiretroviral combinations. It is used with dolutegravir, tenofovir, zidovudine and other agents. It is also approved for chronic hepatitis B, although tenofovir-based products have become the main competitive standard in many markets.

Zidovudine and nevirapine have lost market share because of toxicity, resistance concerns, drug interactions and lower clinical preference compared with newer regimens. WHO guidelines have progressively moved treatment programs toward dolutegravir-based regimens because of superior efficacy, tolerability and resistance performance.[1]

How has the HIV market changed since these drugs launched?

The market has moved through three phases.

Originator-led expansion

Zidovudine was the first widely used antiretroviral and became commercially important after FDA approval in 1987. Lamivudine was approved in 1995, and nevirapine was approved in 1996. The subsequent development of dual- and triple-drug regimens created a major branded HIV market.

GlaxoSmithKline, through Retrovir and Combivir, held a significant position in the early combination market. Boehringer Ingelheim commercialized Viramune, the leading branded nevirapine product. These products generated material revenue before the expansion of generic competition and donor-funded procurement.

Generic and public-sector transition

The HIV market became increasingly dependent on generic suppliers and international procurement mechanisms. Indian manufacturers, including Cipla, Aurobindo Pharma, Mylan, Hetero and Ranbaxy, supplied large volumes to government programs and international organizations.

Fixed-dose combinations reduced pill burden and improved program logistics. Products containing lamivudine, zidovudine and nevirapine were among the early low-cost combinations used in resource-limited settings. Their commercial value came from volume, not premium pricing.

Dolutegravir-based replacement

Current treatment expansion is centered on dolutegravir-based regimens. WHO recommends dolutegravir-containing treatment for most adults and adolescents, subject to patient-specific considerations.[1] TLD has become the principal first-line regimen in many national programs because it combines low cost with strong efficacy and a high barrier to resistance.

This change has structurally reduced demand for nevirapine- and zidovudine-based treatment. The decline is not mainly a patent issue. It is a clinical guideline and procurement issue.

What patents protect lamivudine, nevirapine and zidovudine?

The principal compound patents for all three medicines have expired in major markets.

Drug	Representative originator	Historical patent position	Current status
Zidovudine	Wellcome, later GlaxoSmithKline	Early compound and use patents	Expired
Lamivudine	GlaxoSmithKline and related entities	Compound and use patents	Expired
Nevirapine	Boehringer Ingelheim	Compound and use patents	Expired

The original patents protected the active ingredients, pharmaceutical compositions and therapeutic uses. Their expirations opened the market to generic products in the United States, Europe, India and other major jurisdictions.

Are there active formulation patents?

Formulation patents may exist for specific combinations, dosage forms, manufacturing processes or pediatric presentations, but they do not create a meaningful barrier to the basic active ingredients. A generic manufacturer can generally avoid a formulation patent by using a different excipient system, manufacturing process or dosage presentation.

The commercial relevance of formulation patents is therefore limited to particular products. It does not restore exclusivity for lamivudine, nevirapine or zidovudine as active ingredients.

Is there biosimilar risk?

No. Lamivudine, nevirapine and zidovudine are chemically synthesized small molecules, not biologics. They face generic competition rather than biosimilar competition. The relevant regulatory pathways are abbreviated new drug applications, national generic applications and, in some developing markets, WHO prequalification or procurement qualification.

What is the Orange Book status of these drugs?

The FDA Orange Book historically listed patents and exclusivity information for branded products containing these active ingredients. Any remaining listed patents must be assessed at the specific product and dosage-form level.

The practical Orange Book position is straightforward:

No current compound exclusivity protects the active ingredients.
Historical patents for Retrovir, Epivir, Combivir and Viramune have expired.
Generic approval is principally constrained by product quality, bioequivalence, labeling and manufacturing compliance.
Paragraph IV litigation is no longer the central market event for the core molecules.

A patent challenge against a newly developed formulation could still occur, but a Paragraph IV dispute involving the original active ingredients would have limited commercial significance because generic entry has already occurred.

When did lamivudine, nevirapine and zidovudine lose exclusivity?

The relevant exclusivity periods ended years ago.

Product or active ingredient	Approximate market transition
Zidovudine	Generic availability expanded after early-2000s patent expirations
Lamivudine	Generic competition expanded in the late 2000s
Nevirapine	Generic competition expanded by the late 2000s and early 2010s
Triple combination	No meaningful global exclusivity remains

Exact entry dates vary by country because patent term, regulatory approval and local licensing differed. In many low-income countries, voluntary licensing, non-enforcement policies and donor procurement accelerated generic availability before or around formal patent expiry.

Which companies compete in the market?

The market is fragmented and price-led.

Generic manufacturers

Major suppliers have included:

Cipla
Aurobindo Pharma
Viatris, including legacy Mylan operations
Hetero
Emcure
Laurus Labs
Sun Pharmaceutical Industries
Dr. Reddy's Laboratories
Ranbaxy, before its integration into Sun Pharma
Aspen Pharmacare in selected African markets

The supplier mix changes by tender, country and product qualification. Public procurement often favors manufacturers with WHO prequalification, FDA approval, European regulatory approval or a strong history of supplying the Global Fund and PEPFAR-linked programs.

Originator companies

GlaxoSmithKline and Boehringer Ingelheim remain historically important, but originator revenue from the legacy products is no longer the main market driver. GSK's HIV business has shifted toward dolutegravir-containing products and other newer therapies, while Boehringer's commercial exposure to nevirapine has declined materially.

What is the financial trajectory of the market?

The financial trajectory is one of long-term contraction for the combination and selective durability for lamivudine.

Lamivudine

Lamivudine has the strongest residual commercial position because it is embedded in multiple treatment categories. Demand comes from:

HIV fixed-dose combinations
Chronic hepatitis B treatment
Pediatric HIV products
Public-sector treatment programs
Private-market generic prescriptions

Revenue is constrained by intense generic competition. The active ingredient is strategically important but usually low margin when sold through donor-funded tenders. Higher-value opportunities exist in differentiated formulations, dual therapy, pediatric dispersible tablets and markets with less procurement pressure.

Zidovudine

Zidovudine revenue has declined as it has been displaced by tenofovir and other better-tolerated NRTIs. Remaining demand is associated with:

Pediatric HIV treatment
Maternal and neonatal prevention programs
Salvage or individualized treatment
Certain national formularies
Combination products retained for low-cost procurement

Zidovudine is unlikely to return to sustained growth without a new clinical use or a supply disruption affecting preferred alternatives.

Nevirapine

Nevirapine has faced the most direct substitution risk from newer agents. Its commercial decline reflects:

Lower resistance barrier than dolutegravir
Rash and hepatotoxicity concerns
Drug interactions
Reduced guideline preference
Replacement in first-line treatment
Reduced use in prevention programs

Residual demand persists where treatment programs use legacy stock, pediatric products or low-cost alternatives. The market is defensive rather than expansionary.

How does the triple combination compare with TLD?

Attribute	Lamivudine/zidovudine/nevirapine	Tenofovir/lamivudine/dolutegravir
Clinical position	Legacy regimen	Current preferred regimen in many guidelines
Resistance barrier	Lower	Higher
Tolerability	Less favorable	Generally more favorable
Pill burden	One fixed-dose tablet possible	One fixed-dose tablet
Procurement price	Low	Also highly competitive
Market growth	Declining	Expanding or stable in treatment programs
Patent risk	Negligible	Product- and jurisdiction-specific, but largely generic in many markets
Main use	Residual and specialized	Broad first-line treatment

The triple combination can compete on cost and supply availability, but price alone is insufficient when national guidelines prioritize newer therapy. Its strongest niche is in markets where budget limitations, existing treatment protocols or product availability preserve demand.

What regulatory and procurement factors affect sales?

FDA approval, WHO prequalification and national registration remain important despite patent expiry. Government buyers generally require evidence of:

Bioequivalence
Good manufacturing practice
Stability under local climate conditions
Reliable pharmacovigilance
Acceptable packaging and labeling
Supply continuity
Pediatric dosage suitability

The Global Fund and other procurement agencies have increased quality and documentation requirements. Tender awards can shift rapidly when a supplier fails inspection, cannot meet volume commitments or loses regulatory status.

For low-cost antiretrovirals, manufacturing economics are often more important than intellectual property. Active pharmaceutical ingredient supply, tablet compression capacity, packaging, working capital and tender forecasting determine profitability.

What geographic markets still use these medicines?

Demand is concentrated in sub-Saharan Africa and selected South and Southeast Asian markets. The United States, Western Europe, Japan and other high-income markets have largely moved away from nevirapine- and zidovudine-based first-line therapy.

Residual geographic demand is strongest where:

HIV programs retain legacy regimens
Pediatric dosing options are limited
Donor-funded procurement prioritizes the lowest available price
National guidelines permit older regimens
Local manufacturing or registration supports supply continuity

Lamivudine has a much broader geographic footprint because it remains part of modern HIV combinations and hepatitis B treatment.

What litigation and settlement risks remain?

There is no major global patent litigation trend surrounding the original active ingredients. Historical disputes focused on patent validity, generic entry and licensing in countries with high HIV burdens.

Settlement agreements and voluntary licenses were more important during the early generic-access period than they are today. Current commercial disputes are more likely to involve:

Tender awards
Supply contracts
Regulatory inspection findings
Trademark conflicts
Data exclusivity in individual markets
Product liability or pharmacovigilance
Patent claims covering a new formulation rather than the active ingredient

What generic launch scenarios are most likely?

The base case is continued decline for the fixed triple combination, with stable but low-margin demand in selected markets.

Scenario	Market outcome
Base case	Gradual volume decline; lamivudine remains durable; zidovudine and nevirapine contract
Low-price procurement case	Legacy combination survives in tenders despite weak private-market demand
Supply disruption case	Temporary volume recovery for older products if preferred regimens are unavailable
Pediatric niche case	Stable demand for dispersible or liquid formulations
Regulatory withdrawal case	Further consolidation among qualified suppliers
Repositioning case	Limited opportunity through hepatitis B, pediatric products or differentiated packaging

A generic manufacturer can still generate acceptable returns if it has low-cost production, reliable quality systems and access to large tenders. The opportunity is operational rather than patent-driven.

How strong is the patent estate for these drugs?

The patent estate is weak for the active ingredients and conventional tablets.

Factor	Assessment
Compound patents	Expired
Core composition patents	Expired or commercially immaterial
Method-of-use patents	Historical and generally expired
Formulation patents	Product-specific, limited blocking power
Manufacturing patents	Potentially relevant but avoidable
Biosimilar protection	Not applicable
Paragraph IV exposure	Low for legacy products
Generic entry barrier	Low
Supply-chain barrier	Moderate
Clinical-guideline barrier	High for nevirapine and zidovudine

The main commercial risk is demand erosion, not patent infringement.

Key Takeaways

Lamivudine has the strongest long-term position because it remains part of modern HIV regimens and is also used for hepatitis B.
Zidovudine and nevirapine are legacy antiretrovirals with declining demand.
The lamivudine/zidovudine/nevirapine combination has no meaningful global compound patent protection.
Generic competition is extensive, and pricing is shaped by public tenders and donor procurement.
Dolutegravir-based treatment, especially TLD, is the principal competitive replacement.
Biosimilar risk is irrelevant because all three products are small-molecule drugs.
The remaining commercial opportunity is concentrated in low-income markets, pediatric formulations, prevention programs and supply-constrained tenders.
Financial upside depends on manufacturing efficiency and procurement access rather than exclusivity.

FAQs

Is lamivudine still commercially valuable after patent expiry?

Yes. Lamivudine remains commercially relevant because it is used in HIV and hepatitis B treatment and appears in multiple fixed-dose combinations. Its unit price is low, but aggregate demand remains substantial.

Can a company launch a generic zidovudine/nevirapine/lamivudine tablet?

Generally yes, subject to approval in the target jurisdiction, bioequivalence, manufacturing compliance, labeling and any country-specific patent or regulatory requirements. The original active-ingredient patents do not provide a meaningful global barrier.

Is nevirapine still used in HIV treatment?

Yes, but its use is concentrated in selected legacy, pediatric, prevention and resource-limited settings. It is no longer the preferred first-line agent in many treatment guidelines.

Which product has the highest revenue potential: lamivudine, zidovudine or nevirapine?

Lamivudine has the highest durability and broadest addressable market. Zidovudine and nevirapine have narrower and declining demand profiles.

Could a new formulation revive the market for these drugs?

A pediatric, dispersible, long-acting or heat-stable formulation could create a limited niche. It would not restore broad market growth unless supported by treatment guidelines, procurement inclusion and a meaningful clinical advantage.

References

World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. WHO.
World Health Organization. (2023). Update of recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. WHO.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
UNAIDS. (2023). The path that ends AIDS: 2023 UNAIDS global AIDS update. Joint United Nations Programme on HIV/AIDS.
The Global Fund. (2023). Procurement and market dynamics for HIV medicines. Global Fund to Fight AIDS, Tuberculosis and Malaria.
Glaxo Wellcome plc. (1999). Annual report and accounts. Glaxo Wellcome.
GlaxoSmithKline plc. (2005). Annual report 2005. GlaxoSmithKline.
Boehringer Ingelheim. (2005). Annual report. Boehringer Ingelheim.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	45
DailyMed Link:	lamivudine; nevirapine; zidovudine at DailyMed

Applicant	Application No.	Strength	Dosage Form
⤷ Start Trial	⤷ Start Trial	150MG; 200MG; 300MG	TABLET; ORAL
⤷ Start Trial	⤷ Start Trial	150MG; 200MG; 300MG	TABLET; ORAL
⤷ Start Trial	⤷ Start Trial	30MG; 50MG; 60MG	TABLET, FOR SUSPENSION; ORAL

Lamivudine; nevirapine; zidovudine - Generic Drug Details

What are the generic drug sources for lamivudine; nevirapine; zidovudine and what is the scope of patent protection?

Summary for lamivudine; nevirapine; zidovudine

Recent Clinical Trials for lamivudine; nevirapine; zidovudine

Generic filers with tentative approvals for LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

Anatomical Therapeutic Chemical (ATC) Classes for lamivudine; nevirapine; zidovudine

US Patents and Regulatory Information for lamivudine; nevirapine; zidovudine

Lamivudine, Nevirapine and Zidovudine: Market Dynamics, Patent Status and Financial Trajectory